Gewinn- und Verlustrechnung von Ironwood Pharmaceuticals, Inc.

IRWD tops Q2 earnings estimates, misses on revenues and lifts its 2026 outlook as strong Linzess demand drives year-over-year growth.

Ironwood Pharmaceuticals, Inc. (IRWD) Q2 2026 Earnings Call Transcript

Ironwood Pharmaceuticals NASDAQ: IRWD reported second-quarter results marked by higher LINZESS sales, the start of enrollment in its confirmatory Phase III study of apraglutide, and repayment of its convertible notes, prompting the company to raise its full-year 2026 financial outlook.

Ironwood Pharmaceuticals (IRWD) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.26 per share. This compares to earnings of $0.14 per share a year ago.

[url="]Ironwood Pharmaceuticals, Inc.[/url] (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living w

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its second quarter 2026 results and recent business performance. “Throughout the first half of the year, we have remained laser focused on meaningful execution of our three strategic priorities: maximizing LINZESS, advancing apraglutide, and delivering sustained profit.

Despite the recent market selloff, earnings expectations continue to rise: The S&P 500's Q2 EPS is projected to grow by 37.9%, while net profit margins could reach a 15-year high. Buying the dip can present opportunities for investors. When fear fades, markets have historically returned to fundamentals. Using Seeking Alpha's Quant Tools, I found two Strong Buy stocks, beaten down in the past month, offering both solid growth and value.

Ironwood Pharmaceuticals trades at a 40% discount to its risk-adjusted sum-of-the-parts valuation, anchored by LINZESS and apraglutide. I assign a 'Buy' rating on IRWD and a $6.3 price target, citing a margin of safety, but I also warn of a binary risk tied to apraglutide's pivotal trial. LINZESS faces a patent cliff in 2029, with revenue projected to decay rapidly following the entry of generic products.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced the retirement of Chief Medical Officer and Head of Research and Drug Development Dr. Michael Shetzline and the appointment of Dr. Jeffrey Silber as his successor. Dr. Silber will oversee Research and Drug Development, Regulatory Affairs and Medical Affairs reporting.